Unanswered questions on the use of biologics in pediatric asthma

Antonio Nieto, MD, PhD; Zeinab A. El-Sayed, MD, PhD; René Maximiliano Gómez, PhD; Elham Hossny, MD, PhD; Wang Jiu-Yao, MD, DPhil; Ömer Kalayci, MD; Mário Morais-Almeida; Wanda Phipatanakul, MD; Paulo Marcio Pitrez, MD; César Fireth Pozo Beltrán, MD; Paraskevi Xepapadaki, MD; Nikolaos G. Papadopoulos, MD, PhD

World Allergy Organization Journal (Nov 2023)

Unanswered questions on the use of biologics in pediatric asthma

Antonio Nieto, MD, PhD,
Zeinab A. El-Sayed, MD, PhD,
René Maximiliano Gómez, PhD,
Elham Hossny, MD, PhD,
Wang Jiu-Yao, MD, DPhil,
Ömer Kalayci, MD,
Mário Morais-Almeida,
Wanda Phipatanakul, MD,
Paulo Marcio Pitrez, MD,
César Fireth Pozo Beltrán, MD,
Paraskevi Xepapadaki, MD,
Nikolaos G. Papadopoulos, MD, PhD

Affiliations

Antonio Nieto, MD, PhD: Pediatric Pulmonology & Allergy Unit. Health Research Institute. Children's Hospital La Fe, Valencia, Spain; Corresponding author.
Zeinab A. El-Sayed, MD, PhD: Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt
René Maximiliano Gómez, PhD: School of Health Sciences, Catholic University of Salta, Argentina
Elham Hossny, MD, PhD: Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt
Wang Jiu-Yao, MD, DPhil: Research Center of Allergy, Immunology, and Microbiome (A.I.M.). China Medical University Children's Hospital, Taichung, Taiwan
Ömer Kalayci, MD: Pediatric Allergy and Asthma, Hacettepe University, School of Medicine, Ankara, Turkey
Mário Morais-Almeida: Allergy Center, CUF Descobertas Hospital, CUF Academic and Research Medical Center, Lisbon, Portugal
Wanda Phipatanakul, MD: Pediatric Allergy and Immunology, Boston Children's Hospital, Boston, MA, USA
Paulo Marcio Pitrez, MD: School of Medicine, Pediatric Pulmonary Division, Hospital Moinhos de Vento, Porto Alegre, Brazil
César Fireth Pozo Beltrán, MD: Alergia e Inmunología Clínica Pediátrica, Hospital Infantil de México Federico Gómez, Mexico
Paraskevi Xepapadaki, MD: Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece
Nikolaos G. Papadopoulos, MD, PhD: Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece; Division of Infection, Inflammation & Respiratory Medicine, The University of Manchester, Manchester, UK

Journal volume & issue: Vol. 16, no. 11
p. 100837

Abstract

Read online

The emergence of biologic therapies for the management of asthma has been a revolutionary change in our capacity to manage this disease.Since the launch of omalizumab, several other biologics have been marketed or are close to being marketed, suggesting that a plethora of monoclonal antibodies can be expected in the coming years. This will facilitate the transition to the paradigm of personalized medicine, but on the other hand will decisively further complicate the choice of the most appropriate treatment, in the absence of reliable enough biological markers.For these reasons, along with the relatively short time of use with these treatments, there are recurrently arising questions for which there are not even moderately documented answers, and for which the only solution must be based, with all reservations, on the combination of indirect evidence and expertise. In this paper, we attempt to address such questions, providing relevant commentaries and considering the whole width of the evidence base.

Published in World Allergy Organization Journal

ISSN: 1939-4551 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: https://www.journals.elsevier.com/world-allergy-organization-journal/

About the journal

Abstract

Keywords